['non-small cell lung cancer']
['ldk378']

        Inclusion criteria:

          -  Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK
             rearrangement defined as positive using the FDA approved Vysis ALK Break Apart FISH
             Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity
             criteria) or positive as assessed by the CFDA approved immunohistochemistry (IHC) test
             (Ventana Medical Systems, Inc)

          -  Age 18 years or older at the time of informed consent.

          -  Patients must have stage IIIB or IV NSCLC at the time of study entry and have had
             progressive disease during or after crizotinib treatment whether or not previously
             treated with cytotoxic chemotherapy. If treated with chemotherapy, maximum 2 lines are
             allowed.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to any of the excipients of LDK378

          -  Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or have required increasing doses of steroids within the 2
             weeks prior to study entry to manage CNS symptoms

          -  History of carcinomatous meningitis

          -  Presence or history of a malignant disease other than NSCLC that has been diagnosed
             and/or required therapy within the past 3 years.

          -  clinically significant, uncontrolled heart disease.
      